Early and extended erythropoietin monotherapy after hypoxic ischaemic encephalopathy: a multicentre double-blind pilot randomised controlled trial.

ABSTRACT:

Objective

To examine the feasibility of early and extended erythropoietin monotherapy after hypoxic ischaemic encephalopathy (HIE).

Design

Double-blind pilot randomised controlled trial.

Setting

Eight neonatal units in South Asia.

Patients

Neonates (≥36 weeks) with moderate or severe HIE admitted between 31 December 2022 and 3 May 2023.

Interventions

Erythropoietin (500 U/kg daily) or to the placebo (sham injections using a screen) within 6 hours of birth and continued for 9 days. MRI at 2 weeks of age.

Main outcomes and measures

Feasibility of randomisation, drug administration and assessment of brain injury using MRI.

Results

Of the 154 neonates screened, 56 were eligible; 6 declined consent and 50 were recruited; 43 (86%) were inborn. Me

SUBMITTER: Garegrat R 

PROVIDER: S-EPMC11503063 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature